Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

被引:9
|
作者
Giarola-Silva, Sarah [1 ]
Coelho-dos-Reis, Jordana G. A. [1 ]
Mourao, Marina Moraes [2 ]
Campi-Azevedo, Ana Carolina [1 ]
Nakagaki Silva, Erick E. [2 ]
Luiza-Silva, Maria [3 ]
Martins, Marina Angela [1 ]
de Oliveira Silveira-Cassette, Amanda Cardoso [1 ]
Batista, Mauricio Azevedo [1 ]
Peruhype-Magalhaes, Vanessa [1 ]
do Valle Antonelli, Lis Ribeiro [4 ]
Leite Ribeiro, Jose Geraldo [5 ]
Eloi-Santos, Silvana Maria [1 ,3 ]
Machado, Alexandre Vieira [6 ]
Teixeira-Carvalho, Andrea [1 ]
Martins-Filho, Olindo Assis [1 ]
Silva Araujo, Marcio Sobreira [1 ]
机构
[1] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
[4] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Biol & Imunol Parasitaria, Belo Horizonte, MG, Brazil
[5] Secretaria Estadual Saude Minas Gerais, Belo Horizonte, MG, Brazil
[6] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Imunol Doencas Virais, Belo Horizonte, MG, Brazil
关键词
H1N1; vaccine; AS03; adjuvant; Immune response; Biomarker signature; PANDEMIC H1N1 INFLUENZA; ADVERSE EVENTS; AS03; ADJUVANT; B-LYMPHOCYTES; CHILDREN; CYTOKINE; AGE; IMMUNOGENICITY; INTERLEUKIN-10; SIGNATURES;
D O I
10.1016/j.antiviral.2017.05.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4(+), CDS+ T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tIr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,1-6,1L-1 beta,1L-12,1-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4(+) and CD8(+) T-cells along with promiscuous production of IL-4/IL-5/1L-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8(+) T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4(+)/CD8(+) T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 82
页数:13
相关论文
共 50 条
  • [1] Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza
    Ortqvist, Ake
    Bennet, Rutger
    Rinder, Malin Ryd
    Lindblad, Hans
    Eriksson, Margareta
    VACCINE, 2012, 30 (39) : 5699 - 5702
  • [2] Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients
    Manuel, Oriol
    Pascual, Manuel
    Hoschler, Katja
    Giulieri, Stefano
    Alves, Deolinda
    Ellefsen, Kim
    Bart, Pierre-Alexandre
    Venetz, Jean-Pierre
    Calandra, Thierry
    Cavassini, Matthias
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (02) : 248 - 256
  • [3] Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
    Walker, Woolf T.
    Faust, Saul N.
    EXPERT REVIEW OF VACCINES, 2010, 9 (12) : 1385 - 1398
  • [4] Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients
    Salles, M. J. C.
    Sens, Y. A. S.
    Malafronte, P.
    Souza, J. F.
    Vilas Boas, L. S.
    Machado, C. M.
    TRANSPLANT INFECTIOUS DISEASE, 2012, 14 (06) : 564 - 574
  • [5] Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
    Teresa Herrera, Ma
    Gonzalez, Yolanda
    Juarez, Esmeralda
    Hernandez-Sanchez, Fernando
    Carranza, Claudia
    Sarabia, Carmen
    Guzman-Beltran, Silvia
    Eugenia Manjarrez, Ma
    Munoz-Torrico, Marcela
    Garcia-Garcia, Lourdes
    Sada, Eduardo
    Torres, Martha
    BMC INFECTIOUS DISEASES, 2013, 13
  • [6] Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial
    Yang, William H.
    Dionne, Marc
    Kyle, Michael
    Aggarwal, Naresh
    Li, Ping
    Madariaga, Miguel
    Godeaux, Olivier
    Vaughn, David W.
    VACCINE, 2013, 31 (40) : 4389 - 4397
  • [7] Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children
    Ortqvist, Ake
    Bennet, Rutger
    Hamrin, Johan
    Rinder, Malin Ryd
    Lindblad, Hans
    Ohd, Joanna Nederby
    Eriksson, Margareta
    VACCINE, 2015, 33 (22) : 2558 - 2561
  • [8] HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children
    Leahy, Timothy R.
    Goode, Michelle
    Lynam, Paul
    Gavin, Patrick J.
    Butler, Karina M.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2014, 8 (03) : 360 - 366
  • [9] Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies
    Garcia-Sicilia, Jose
    Aristegui, Javier
    Omenaca, Felix
    Carmona, Alfonso
    Tejedor, Juan C.
    Merino, Jose M.
    Garcia-Corbeira, Pilar
    Walravens, Karl
    Bambure, Vinod
    Moris, Philippe
    Caplanusi, Adrian
    Gillard, Paul
    Dieussaert, Ilse
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (10) : 2359 - 2369
  • [10] Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults
    Nielsen, Allan Bybeck
    Nielsen, Henriette Schjonning
    Nielsen, Lars
    Thybo, Soren
    Kronborg, Gitte
    VACCINE, 2012, 30 (49) : 7067 - 7071